Akero Therapeutics, Inc. (AKRO) - Shares of the clinical-stage biotechnology company jumped over 50% in after hours on Tuesday. The company announced positive histological data across all efruxifermin dose groups in 16-week phase 2a BALANCED study in NASH patients.
